Literature DB >> 8301302

Immunotherapy for multiple sclerosis.

R A Hughes.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8301302      PMCID: PMC485031          DOI: 10.1136/jnnp.57.1.3

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  40 in total

1.  Deaths after total lymphoid irradiation for multiple sclerosis.

Authors:  S D Cook; R Troiano; G Zito; R Rohowsky-Kochan; C Sheffit; P C Dowling; C K Devereux
Journal:  Lancet       Date:  1989-07-29       Impact factor: 79.321

2.  Intravenous methylprednisolone for multiple sclerosis in relapse.

Authors:  M P Barnes; D E Bateman; P G Cleland; D J Dick; T J Walls; P K Newman; M Saunders; P J Tilley
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-02       Impact factor: 10.154

3.  Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo--final report.

Authors:  A S Rose; J W Kuzma; J F Kurtzke; N S Namerow; W A Sibley; W W Tourtellotte
Journal:  Neurology       Date:  1970-05       Impact factor: 9.910

4.  Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs.

Authors:  B O Khatri; M P McQuillen; G J Harrington; D Schmoll; R G Hoffmann
Journal:  Neurology       Date:  1985-03       Impact factor: 9.910

5.  Systemic alpha-interferon therapy of multiple sclerosis.

Authors:  R L Knobler; H S Panitch; S L Braheny; J C Sipe; G P Rice; J R Huddlestone; G S Francis; C K Hooper; R M Kamin-Lewis; K P Johnson
Journal:  Neurology       Date:  1984-10       Impact factor: 9.910

6.  [Side effects of azathioprine (Imurel). Apropos of 313 patients treated for multiple sclerosis. Review of the literature].

Authors:  J J Ventre; M Guillot; C Confavreux; J C Evreux; G Aimard
Journal:  Therapie       Date:  1985 May-Jun       Impact factor: 2.070

7.  Systemic recombinant alpha-2 interferon therapy in relapsing multiple sclerosis.

Authors:  D L Camenga; K P Johnson; M Alter; C D Engelhardt; P S Fishman; J I Greenstein; A S Haley; R L Hirsch; J E Kleiner; V Y Kofie
Journal:  Arch Neurol       Date:  1986-12

8.  Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment.

Authors:  L J Kinlen
Journal:  Am J Med       Date:  1985-01-21       Impact factor: 4.965

9.  Multiple sclerosis: MRI and clinical correlation.

Authors:  M K Edwards; M R Farlow; J C Stevens
Journal:  AJR Am J Roentgenol       Date:  1986-09       Impact factor: 3.959

10.  "Bolus" methylprednisolone versus ACTH in the treatment of multiple sclerosis.

Authors:  G Abbruzzese; C Gandolfo; C Loeb
Journal:  Ital J Neurol Sci       Date:  1983-06
View more
  3 in total

Review 1.  Outcomes assessment of drug treatment in multiple sclerosis clinical trials.

Authors:  M Malone; B Lomaestro
Journal:  Pharmacoeconomics       Date:  1996-03       Impact factor: 4.981

Review 2.  More immunotherapy for multiple sclerosis.

Authors:  R A Hughes; B Sharrack
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-09       Impact factor: 10.154

Review 3.  Neurology.

Authors:  R S Howard
Journal:  BMJ       Date:  1994-08-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.